ReviewAntimicrobial agents and chemotherapy2022
New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus.
Review in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 61 citations in OpenAlex.
- Exploration of the protein and pharmacological landscape of monkeypox virus treatment: from entry point to end point.Molecular diversity · 2026Review
- Therapeutic Innovations for Monkeypox Inhibition.International journal of molecular sciences · 2026Review
- Trends of Pathogenicity and Potential Risk Evaluation of Central African Mpox Variant to Cause Global Public Health Emergency: A Cross-Sectional Analysis.Health science reports · 2026Article
- Drug repurposing against viral infections (2020-2025): clinical trials, computational strategies, and therapeutic interventions.Inflammopharmacology · 2026Review
- Tecovirimat for the Treatment of Mpox.The New England journal of medicine · 2026Article
- The emergence of Clade IIb and Ib mpox viruses: a state-of-the-art review.Annals of medicine and surgery (2012) · 2026Review
- Review
- Computational analysis and validation of UGT1A1/4 missense variants impacting tecovirimat metabolism in monkeypox patients.Frontiers in systems biology · 2026Article
- Structural and dynamic insights into F13L variations in monkeypox virus and their impact on tecovirimat resistance.Virology journal · 2025Article
- Re-emergence and clinical management of monkeypox: insights into viral biology, therapeutics, and vaccination.Molecular biology reports · 2025Review
- Strategies and efforts in circumventing the emergence of antiviral resistance against conventional antivirals.npj antimicrobials and resistance · 2025Review
- 3D-EDiffMG: 3D equivariant diffusion-driven molecular generation to accelerate drug discovery.Journal of pharmaceutical analysis · 2025Article
- Ocular Manifestations of Mpox and Other Poxvirus Infections: Clinical Insights and Emerging Therapeutic and Preventive Strategies.Vaccines · 2025Review
- Early clinical experience using tecovirimat during the 2022 mpox epidemic in Toronto underscores ongoing clinical equipoise and the need for randomized trials.The Journal of antimicrobial chemotherapy · 2025Observational
- Monkeypox: Prevention Strategies and Challenges: Updated Review.Health science reports · 2025Article
- Vaccines and Antiviral Therapies for Mpox Virus in Pregnant and Breastfeeding Women: Efficacy and Maternal-Child Outcomes.Viruses · 2025Review
- Antiviral Effects of Tecovirimat and Cellular Ultrastructural Changes in Human Bronchial Epithelial Cell Line Following Monkeypox Virus Infection.International journal of molecular sciences · 2025Article
- Monkeypox in a Non-endemic Setting: Challenges in the Diagnosis and Management of an Atypical Case.Cureus · 2025Article
- "Mpox in MSM: Tackling stigma, minimizing risk factors, exploring pathogenesis, and treatment approaches".Biomedical journal · 2025Review
- International healthcare workers' experiences and perceptions of the 2022 multi-country mpox outbreak.PLOS global public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Tecovirimat is an antiviral drug initially developed against variola virus (VARV) to treat smallpox infection. Due to its mechanism of action, it has activity against the family of orthopoxviruses, including vaccinia and the human monkeypox virus (HMPXV). Efficacy studies have thus far been limited to animal models, with human safety trials showing no serious adverse events. Currently approved by the FDA only for the treatment of smallpox, tecovirimat shows promise for the treatment of HMPXV. Tecovirimat has been prescribed via an expanded access for an investigational new drug protocol during the 2022 outbreak. This review will examine the literature surrounding tecovirimat's mechanism of action, pharmacokinetics, safety, efficacy, and potential for resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.